Changes in Beneficial Ownership · 4
Bluejay Diagnostics, Inc.
BJDXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-17
- Issuer
- Bluejay Diagnostics, Inc.
- Issuer CIK
- 0001704287
- Trading symbol
- BJDX
Reporting owner 1
- Name
- CHASE DONALD R
- Reporting owner CIK
- 0001247473
- Relationship
- Director
- Address
- C/O BLUEJAY DIAGNOSTICS, INC., 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA, 01720
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 2.075 | 2026-08-17 | A · Form 4 | 100,000 | A | 0 | [F1] | 2031-08-17 | Common Stock | 100,000 | 100,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.↩ 1
Signature 1
- Signed
- /s/ Donald R Chase
- Date
- 2026-08-18
Company context
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.